Magle Chemoswed Holding AB stock analysis
Want to see SE:MAGLE full AI Analyst Report?
Magle Chemoswed Holding AB (MAGLE) Stock Price & Analysis
MAGLE Stock Chart & Stats
- Day’s Range
- SEK 0.22 - SEK 0.28
- 52-Week Range
- SEK 0.12 - SEK 21.00
- Previous Close
- SEK 0.25
- Volume
- N/A
- Average Volume (3M)
- 302.18K
- Market Cap
- SEK 39.40M
- Enterprise Value
- SEK 363.38M
- Total Cash (Recent Filing)
- SEK 2.08M
- Total Debt (Recent Filing)
- SEK 343.99M
- Price to Earnings (P/E)
- ―
- Beta
- 0.22
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Apr 26, 2024
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Positive TTM revenue growth indicates that customer demand for the company’s development and manufacturing services is expanding. If maintained, this broader revenue base can support better operating leverage and provide a foundation for rebuilding profitability over the next several quarters.
Gross Margin
A gross margin of approximately 54% shows that the company’s services retain meaningful economic value before operating expenses. Although margin has compressed, this remaining gross-profit pool could support recovery if management brings the cost structure back into alignment with revenue.
Integrated CDMO Offering
Magle combines pharmaceutical development, analytical work, and production across APIs and finished dosage forms. This integrated CDMO model can support customers through multiple stages of regulated product development, potentially deepening relationships and broadening service revenue.
Bears Say
Severe Profitability Deterioration
The sharp move to a deeply negative net margin shows that current operating costs are overwhelming gross profit despite revenue growth. Persistent losses could limit internal reinvestment, weaken financial resilience, and make a durable earnings recovery dependent on substantial cost improvement.
Persistent Cash Burn
Meaningfully negative operating and free cash flow indicate that the business is not currently converting activity into funding for itself. Continued cash burn can restrict investment flexibility and may require additional financing if operations do not return to positive cash generation.
Rising Leverage And Equity Erosion
Debt now exceeds equity while the equity cushion has weakened in line with losses, reducing balance-sheet flexibility. If negative results persist, higher leverage can increase funding pressure and leave fewer resources available to absorb setbacks or finance strategic growth.
Magle Chemoswed Holding AB News
MAGLE FAQ
What was Magle Chemoswed Holding AB’s price range in the past 12 months?
What is Magle Chemoswed Holding AB’s market cap?
When is Magle Chemoswed Holding AB’s upcoming earnings report date?
How were Magle Chemoswed Holding AB’s earnings last quarter?
Is Magle Chemoswed Holding AB overvalued?
Does Magle Chemoswed Holding AB pay dividends?
What is Magle Chemoswed Holding AB’s EPS estimate?
How many shares outstanding does Magle Chemoswed Holding AB have?
What happened to Magle Chemoswed Holding AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Magle Chemoswed Holding AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Aaron Wong
- Employees
- 150
- Website
- maglegroup.com
- Address
- Agneslundsvägen 27, Malmö, SN, 212 15, SE
Magle Chemoswed Holding AB (MAGLE) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 1 | 0 | 11 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:BINVBioInvent International AB | ||
| SE:NEEMS.BScandinavian ChemoTech AB Class B | ||
| SE:ELICElicera Therapeutics AB | ||
| SE:SPAGOSpago Nanomedical AB | ||
| SE:CANTACantargia AB |








